Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;9:730240. doi: 10.3389/fcell.2021.730240

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Lu, Jin, Du, Hu, Wei, Wang, Li and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Expression and correlation of ICB and lenvatinib targets. (A) Comparison of ICB and lenvatinib target genes expression in tumor tissue and corresponding normal tissue. The cancer types in red text represent high expression of both lenvatinib (≥4 large red circles) and ICB (≥2 large red circles) target genes; green text represents moderate expression defined as higher expression of either lenvatinib (≥4 large red circles) or ICB (≥2 large red circles) target genes; blue text represents low expression of both lenvatinib and ICB target genes (no large red circles for either). (B) PPI network construction of lenvatinib and ICB target genes. (C) Correlation coefficient graph of ICB and lenvatinib target genes in pan-cancer. Numbers and the pie chart size correspond to the Pearson correlation coefficient (r value). The black boxes are the intersecting sections, and the red highlighted text and circles are r ≥ 0.1. BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; ESCA, esophageal carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PAAD, prostate adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; THYM, thymoma; ICB, immune-checkpoint blockade; FLT1 (VEGFR1), vascular endothelial growth factor receptor 1; KDR (VEGFR2), vascular endothelial growth factor receptor 2; FLT4 (VEGFR3), vascular endothelial growth factor receptor 3; FGFR, fibroblast growth factor receptor; PDGFR, platelet derived growth factor receptor; KIT, stem cell factor receptor; RET, the rearranged during transfection; PDCD1 (PD-1), programmed cell death 1; CD274 (PD-L1), programmed cell death ligand 1; LAG3, lymphocyte-activation protein 3; CTLA4, cytotoxic T-lymphocyte-associated antigen 4.